Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...

Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a ...

Although lung cancer survival is improving in the United States, 21% of patients with lung cancer did not receive treatment ...

Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...

CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.

Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer.

Though lung cancer survival rates are improving, lung cancer is still the leading cause of cancer deaths in the US.

Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis ...

Edgardo S. Santos, MD, FACP, FASCO, discussed the barriers to precision medicine in lung cancer treatment, including patient ...

Researchers from the University of Michigan have developed a way of detecting circulating tumor cells in the bloodstream of ...